mepitiostane

Mepitiostane, sold under the brand name Thioderon, is an orally active antiestrogen and anabolic–androgenic steroid (AAS) of the dihydrotestosterone (DHT) group which is marketed in Japan as an antineoplastic agent for the treatment of breast cancer. It is a prodrug of epitiostanol. The drug was patented and described in 1968.

Research

39 papers

[Complete remission by mepitiostane in hypoplastic leukemia].[Rinsho ketsueki] The Japanese journal of clinical hematology · 1989
Adjuvant endocrine therapy for operable breast cancer using the antiestrogen mepitiostane: a preliminary report.Gan · 1980
Determination of mepitiostane metabolites in human urine by liquid chromatography/tandem mass spectrometry for sports drug testing.Journal of pharmaceutical and biomedical analysis · 2015
Regression of a presumed meningioma with the antiestrogen agent mepitiostane. Case report.Journal of neurosurgery · 2000
[Effect of an oral anti-estrogen agent (mepitiostane) on the regression of intracranial meningiomas in the elderly].Brain and nerve = Shinkei kenkyu no shinpo · 2014

via PubMed

Wikidata facts

Mass: 404.274902

Show 3 more facts

isomeric SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC4(CCCC4)OC)CC[C@@H]5[C@@]3(C[C@@H]6[C@H](C5)S6)C
canonical SMILES: CC12CCC3C(C1CCC2OC4(CCCC4)OC)CCC5C3(CC6C(C5)S6)C
chemical formula: C₂₅H₄₀O₂S

Sources (2)

via Wikidata · CC0

~2 min read

Article

9 sections

Contents

Medical uses
Side effects
Pharmacology
Pharmacodynamics
Pharmacokinetics
Chemistry
Society and culture
Generic names
References

==Medical uses== Mepitiostane is used as an antiestrogen and antineoplastic agent in the treatment of breast cancer. It is also used as an AAS in the treatment of anemia of renal failure. A series of case reports have found it to be effective in the treatment of an estrogen receptor (ER)-dependent meningiomas as well.